公开(公告)号：WO2004103344A1

公开(公告)日：2004-12-02

申请号：PCT/US2003/015771

申请日：2003-05-20

Applicant: ARONEX PHARMACEUTICALS, INC. ,  LEWIS, Jonathan ,  HOOS, Axel ,  GALE, Robert, Peter

Inventor： LEWIS, Jonathan ,  HOOS, Axel ,  GALE, Robert, Peter

IPC: A61K9/127

CPC classification number: A61K9/19 ,  A61K9/127 ,  A61K31/28 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to methods for treating cancer comprising administering a combination of a liposomal platinum complex and one or more additional anticancer agents, pharmaceutical compositions comprising a liposomal platinum complex and one or more additional anticancer agents, and kits comprising unit doses of a liposomal platinum complex and one or more additional anticancer agents.

Abstract translation: 本发明涉及治疗癌症的方法，包括给予脂质体铂络合物和一种或多种另外的抗癌剂的组合，包含脂质体铂络合物和一种或多种另外的抗癌剂的药物组合物，以及包含单位剂量的脂质体铂 复合物和一种或多种另外的抗癌剂。

公开(公告)号：WO2004103382A1

公开(公告)日：2004-12-02

申请号：PCT/US2003/015772

申请日：2003-05-20

Applicant: ARONEX PHARMACEUTICALS, INC. ,  LEWIS, Jonathan ,  HOOS, Axel ,  GALE, Robert, Peter

Inventor： LEWIS, Jonathan ,  HOOS, Axel ,  GALE, Robert, Peter

IPC: A61K33/24

CPC classification number: A61K9/127 ,  A61K31/28 ,  A61K31/555 ,  A61K33/24 ,  A61K47/6911 ,  A61K2300/00

Abstract: The present invention relates to methods for treating cancer comprising administering a combination of 5-fluorouracil or a derivative thereof and a liposomal platinum complex. Pharmaceutical compositions comprising 5-fluorouracil or a derivative thereof and a liposomal platinum complex, and kits comprising unit doses of 5-fluorouracil or a derivative thereof and liposomal platinum complex.

Abstract translation: 本发明涉及治疗癌症的方法，包括给予5-氟尿嘧啶或其衍生物和脂质体铂络合物的组合。 包含5-氟尿嘧啶或其衍生物和脂质体铂络合物的药物组合物，以及包含单位剂量的5-氟尿嘧啶或其衍生物和脂质体铂络合物的试剂盒。

公开(公告)号：WO2004105747A1

公开(公告)日：2004-12-09

申请号：PCT/US2003/015770

申请日：2003-05-20

Applicant: ARONEX PHARMACEUTICALS, INC ,  LEWIS, Jonathan ,  HOOS, Axel ,  GALE, Robert, Peter

Inventor： LEWIS, Jonathan ,  HOOS, Axel ,  GALE, Robert, Peter

IPC: A61K31/19

CPC classification number: A61K31/555 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/19 ,  A61K31/28 ,  A61K31/282 ,  A61K31/7068 ,  A61K33/24 ,  A61K45/06 ,  A61K47/6911 ,  A61K2300/00

Abstract: The present invention relates to methods for treating cancer comprising administering a combination of capecitabine and a liposomal platinum complex, pharmaceutical compositions comprising capecitabine and a liposomal platinum complex, and kits comprising unit dosage forms of capecitabine and a liposomal platinum complex.

Abstract translation: 本发明涉及治疗癌症的方法，包括给予卡培他滨和脂质体铂络合物的组合物，包含卡培他滨和脂质体铂络合物的药物组合物，以及包含卡培他滨单体剂型和脂质体铂络合物的试剂盒。

公开(公告)号：WO2014193898A1

公开(公告)日：2014-12-04

申请号：PCT/US2014/039686

申请日：2014-05-28

Applicant: MERCK SHARP & DOHME CORP. ,  GLAXOSMITHKLINE LLC ,  HOOS, Axel ,  ORFORD, Keith, W. ,  CHUN, Patrick ,  SRIRAM, Venkataraman ,  PINHEIRO, Elaine, M. ,  EBBINGHAUS, Scot, W.

Inventor： HOOS, Axel ,  ORFORD, Keith, W. ,  CHUN, Patrick ,  SRIRAM, Venkataraman ,  PINHEIRO, Elaine, M. ,  EBBINGHAUS, Scot, W.

IPC: A61K31/506 ,  C07D413/12 ,  A61K31/519 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K31/506 ,  A61K31/519 ,  A61K2039/505 ,  C07K16/2818 ,  C07K2317/76 ,  A61K2300/00

Abstract: A novel combination comprising a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and a PD-1 antagonist; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf and/or immune modulation through PD-1 is beneficial, e.g., cancer.

Abstract translation: 包含B-Raf抑制剂，特别是N- {3- [5-（2-氨基-4-嘧啶基）-2-（1,1-二甲基乙基）-1,3-噻唑-4-基] - 2-氟苯基} -2,6-二氟苯磺酰胺或其药学上可接受的盐，MEK抑制剂N- {3- [3-环丙基-5-（2-氟-4-碘 - 苯基氨基）6,8-二甲基 - 3,4,7-三氧代-3,4,6,7-四氢-2H-吡啶并[4,3-d]嘧啶-1-基]苯基}乙酰胺或其药学上可接受的盐或溶剂化物，和PD -1拮抗剂; 包含其的药物组合物和使用这些组合和组合物治疗MEK和/或B-Raf的抑制和/或通过PD-1的免疫调节有利的条件的方法，例如癌症。